{"id":173881,"date":"2024-05-31T20:00:00","date_gmt":"2024-06-01T00:00:00","guid":{"rendered":"https:\/\/platohealth.ai\/?p=173881"},"modified":"2024-05-31T20:00:00","modified_gmt":"2024-06-01T00:00:00","slug":"efficacy-of-biofeedback-in-the-treatment-of-tic-disorder","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/efficacy-of-biofeedback-in-the-treatment-of-tic-disorder\/","title":{"rendered":"Efficacy of Biofeedback in the Treatment of Tic Disorder","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"\n
\n

Studies<\/h3>\n\n\n\n\n\n\n\n\n\n <\/tr>\n<\/table><\/div>\n
\n

Detailed Descriptions<\/h3>\n

Study First Submitted Date<\/td>\n2022-03-18<\/td>\n<\/tr>\n
Study First Posted Date <\/td>\n2022-05-05<\/td>\n<\/tr>\n
Last Update Posted Date<\/td>\n2022-10-24<\/td>\n<\/tr>\n
Start Month Year<\/td>\nJune 1, 2024<\/td>\n<\/tr>\n
Primary Completion Month Year<\/td>\nDecember 31, 2026<\/td>\n<\/tr>\n
Verification Month Year<\/td>\nOctober 2022<\/td>\n<\/tr>\n
Verification Date<\/td>\n2022-10-31<\/td>\n<\/tr>\n
Last Update Posted Date<\/td>\n2022-10-24<\/td>\n<\/tr>\n
\n\n\n
Sequence:<\/td>\n20802855<\/td>\n<\/tr>\n
Description<\/td>\nThis study intends to investigate the efficacy of EEG biofeedback and drug therapy on clinical symptoms, cognitive flexibility and quality of life in chronic tic disorder and Tourette syndrome through a randomized controlled study.<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Facilities<\/h3>\n\n\n <\/tr>\n\n\n\n\n\n
Sequence:<\/td>\n200793616<\/td>\n<\/tr>\n
Name<\/td>\nChildren's hospital of Fundan University<\/td>\n<\/tr>\n
City<\/td>\nShanghai<\/td>\n<\/tr>\n
State<\/td>\nShanghai<\/td>\n<\/tr>\n
Zip<\/td>\n201102<\/td>\n<\/tr>\n
Country<\/td>\nChina<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Facility Contacts<\/h3>\n\n\n\n\n\n\n\n\n
Sequence:<\/td>\n28220306<\/td>\n<\/tr>\n
Facility Id<\/td>\n200793616<\/td>\n<\/tr>\n
Contact Type<\/td>\nprimary<\/td>\n<\/tr>\n
Name<\/td>\nDing Qiang, master<\/td>\n<\/tr>\n
Email<\/td>\njohndean@foxmail.com<\/td>\n<\/tr>\n
Phone<\/td>\n18818239447<\/td>\n<\/tr>\n
Phone Extension<\/td>\n201102<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Browse Interventions<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n96375173<\/td>\nSequence:<\/td>\n96375174<\/td>\nSequence:<\/td>\n96375175<\/td>\nSequence:<\/td>\n96375176<\/td>\nSequence:<\/td>\n96375177<\/td>\nSequence:<\/td>\n96375178<\/td>\nSequence:<\/td>\n96375179<\/td>\nSequence:<\/td>\n96375180<\/td>\nSequence:<\/td>\n96375181<\/td>\nSequence:<\/td>\n96375182<\/td>\nSequence:<\/td>\n96375183<\/td>\nSequence:<\/td>\n96375184<\/td>\nSequence:<\/td>\n96375185<\/td>\nSequence:<\/td>\n96375186<\/td>\nSequence:<\/td>\n96375187<\/td>\nSequence:<\/td>\n96375188<\/td>\nSequence:<\/td>\n96375189<\/td>\nSequence:<\/td>\n96375190<\/td>\n<\/tr>\n
Mesh Term<\/td>\nAripiprazole<\/td>\nMesh Term<\/td>\nAntidepressive Agents<\/td>\nMesh Term<\/td>\nPsychotropic Drugs<\/td>\nMesh Term<\/td>\nAntipsychotic Agents<\/td>\nMesh Term<\/td>\nTranquilizing Agents<\/td>\nMesh Term<\/td>\nCentral Nervous System Depressants<\/td>\nMesh Term<\/td>\nPhysiological Effects of Drugs<\/td>\nMesh Term<\/td>\nDopamine Agonists<\/td>\nMesh Term<\/td>\nDopamine Agents<\/td>\nMesh Term<\/td>\nNeurotransmitter Agents<\/td>\nMesh Term<\/td>\nMolecular Mechanisms of Pharmacological Action<\/td>\nMesh Term<\/td>\nSerotonin 5-HT1 Receptor Agonists<\/td>\nMesh Term<\/td>\nSerotonin Receptor Agonists<\/td>\nMesh Term<\/td>\nSerotonin Agents<\/td>\nMesh Term<\/td>\nSerotonin 5-HT2 Receptor Antagonists<\/td>\nMesh Term<\/td>\nSerotonin Antagonists<\/td>\nMesh Term<\/td>\nDopamine D2 Receptor Antagonists<\/td>\nMesh Term<\/td>\nDopamine Antagonists<\/td>\n<\/tr>\n
Downcase Mesh Term<\/td>\naripiprazole<\/td>\nDowncase Mesh Term<\/td>\nantidepressive agents<\/td>\nDowncase Mesh Term<\/td>\npsychotropic drugs<\/td>\nDowncase Mesh Term<\/td>\nantipsychotic agents<\/td>\nDowncase Mesh Term<\/td>\ntranquilizing agents<\/td>\nDowncase Mesh Term<\/td>\ncentral nervous system depressants<\/td>\nDowncase Mesh Term<\/td>\nphysiological effects of drugs<\/td>\nDowncase Mesh Term<\/td>\ndopamine agonists<\/td>\nDowncase Mesh Term<\/td>\ndopamine agents<\/td>\nDowncase Mesh Term<\/td>\nneurotransmitter agents<\/td>\nDowncase Mesh Term<\/td>\nmolecular mechanisms of pharmacological action<\/td>\nDowncase Mesh Term<\/td>\nserotonin 5-ht1 receptor agonists<\/td>\nDowncase Mesh Term<\/td>\nserotonin receptor agonists<\/td>\nDowncase Mesh Term<\/td>\nserotonin agents<\/td>\nDowncase Mesh Term<\/td>\nserotonin 5-ht2 receptor antagonists<\/td>\nDowncase Mesh Term<\/td>\nserotonin antagonists<\/td>\nDowncase Mesh Term<\/td>\ndopamine d2 receptor antagonists<\/td>\nDowncase Mesh Term<\/td>\ndopamine antagonists<\/td>\n<\/tr>\n
Mesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Conditions<\/h3>\n\n\n\n\n
Sequence:<\/td>\n52378172<\/td>\n<\/tr>\n
Name<\/td>\nTic Disorders<\/td>\n<\/tr>\n
Downcase Name<\/td>\ntic disorders<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Id Information<\/h3>\n\n\n\n\n <\/tr>\n <\/tr>\n <\/tr>\n<\/table><\/div>\n
\n

Countries<\/h3>\n

Sequence:<\/td>\n40306145<\/td>\n<\/tr>\n
Id Source<\/td>\norg_study_id<\/td>\n<\/tr>\n
Id Value<\/td>\nTD_BF_RCT20220318<\/td>\n<\/tr>\n
\n\n\n\n
Sequence:<\/td>\n42728769<\/td>\n<\/tr>\n
Name<\/td>\nChina<\/td>\n<\/tr>\n
Removed<\/td>\nFalse<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Groups<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n55823438<\/td>\nSequence:<\/td>\n55823439<\/td>\n<\/tr>\n
Group Type<\/td>\nExperimental<\/td>\nGroup Type<\/td>\nActive Comparator<\/td>\n<\/tr>\n
Title<\/td>\nBiofeedback therapy<\/td>\nTitle<\/td>\nDrug therapy<\/td>\n<\/tr>\n
Description<\/td>\nthree times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training (using the Infiniti3000A biofeedback system Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.<\/td>\nDescription<\/td>\nConsidering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Interventions<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n52688379<\/td>\nSequence:<\/td>\n52688380<\/td>\n<\/tr>\n
Intervention Type<\/td>\nDrug<\/td>\nIntervention Type<\/td>\nDevice<\/td>\n<\/tr>\n
Name<\/td>\nDrug Aripiprazole<\/td>\nName<\/td>\nbiofeedback<\/td>\n<\/tr>\n
Description<\/td>\nConsidering the patients with chronic tic disorder (chronic motor or vocal tic disorder or Tourette's disorder), aripiprazole was selected as a single drug with constant dose during the treatment. In case of extrapyramidal side effects, benhexol was given to reduce the extrapyramidal side effects, and the dosage and duration of medication were recorded<\/td>\nDescription<\/td>\nBiofeedback therapy Biofeedback therapy, three times a week, every other day interval, 30 minutes each time, each subject received 20 biofeedback training\uff08using the Infiniti3000A biofeedback system\uff0cThought Technology Ltd.\uff09.Patients in the theta group decreased the theta amplitude at Cz. Patients in the theta group received positive feedback when their theta activity was below the feedback threshold.<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Keywords<\/h3>\n\n\n\n\n
Sequence:<\/td>\n80151470<\/td>\nSequence:<\/td>\n80151471<\/td>\nSequence:<\/td>\n80151472<\/td>\nSequence:<\/td>\n80151473<\/td>\n<\/tr>\n
Name<\/td>\nbiofeedback<\/td>\nName<\/td>\ndrug therapy<\/td>\nName<\/td>\nClinical Efficacy<\/td>\nName<\/td>\nCognitive flexibility<\/td>\n<\/tr>\n
Downcase Name<\/td>\nbiofeedback<\/td>\nDowncase Name<\/td>\ndrug therapy<\/td>\nDowncase Name<\/td>\nclinical efficacy<\/td>\nDowncase Name<\/td>\ncognitive flexibility<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Outcomes<\/h3>\n\n\n\n\n\n <\/tr>\n\n
Sequence:<\/td>\n178143717<\/td>\nSequence:<\/td>\n178143718<\/td>\nSequence:<\/td>\n178143719<\/td>\nSequence:<\/td>\n178143720<\/td>\nSequence:<\/td>\n178143721<\/td>\nSequence:<\/td>\n178143722<\/td>\nSequence:<\/td>\n178143723<\/td>\nSequence:<\/td>\n178143724<\/td>\nSequence:<\/td>\n178143725<\/td>\nSequence:<\/td>\n178143726<\/td>\nSequence:<\/td>\n178143727<\/td>\nSequence:<\/td>\n178143728<\/td>\nSequence:<\/td>\n178143729<\/td>\nSequence:<\/td>\n178143730<\/td>\nSequence:<\/td>\n178143731<\/td>\nSequence:<\/td>\n178143732<\/td>\n<\/tr>\n
Outcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nprimary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\nOutcome Type<\/td>\nsecondary<\/td>\n<\/tr>\n
Measure<\/td>\nYale global tic severity scale<\/td>\nMeasure<\/td>\nYale global tic severity scale<\/td>\nMeasure<\/td>\nYale global tic severity scale<\/td>\nMeasure<\/td>\nYale global tic severity scale<\/td>\nMeasure<\/td>\nWisconsin Card Sorting Test<\/td>\nMeasure<\/td>\nWisconsin Card Sorting Test<\/td>\nMeasure<\/td>\nWisconsin Card Sorting Test<\/td>\nMeasure<\/td>\nWisconsin Card Sorting Test<\/td>\nMeasure<\/td>\nColor-word Stroop task<\/td>\nMeasure<\/td>\nThe Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)<\/td>\nMeasure<\/td>\nThe parent version of Swanson, Nolan, and Pelham-IV(SNAP-IV)<\/td>\nMeasure<\/td>\nChildren' s Depression Inventory(CDI)<\/td>\nMeasure<\/td>\nThe Screen for Child Anxiety Related Emotional Disorders(SCARED)<\/td>\nMeasure<\/td>\nConners' Parent Rating Scale-Revised\uff08CPRS-R\uff09<\/td>\nMeasure<\/td>\nThe Clinical Global Impression-severity scale<\/td>\nMeasure<\/td>\nClinical Global Impressions-Improvement scale<\/td>\n<\/tr>\n
Time Frame<\/td>\nbaseline assessment (T0)<\/td>\nTime Frame<\/td>\nassessment after 4 weeks of treatment (T1)<\/td>\nTime Frame<\/td>\nassessment after 8 weeks of treatment (T2)<\/td>\nTime Frame<\/td>\n3-month follow-up after completion of treatment (T3).<\/td>\nTime Frame<\/td>\nbaseline assessment (T0)<\/td>\nTime Frame<\/td>\nassessment after 4 weeks of treatment (T1)<\/td>\nTime Frame<\/td>\nassessment after 8 weeks of treatment (T2)<\/td>\nTime Frame<\/td>\n3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cbaseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cbaseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cbaseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cbaseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0caseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0caseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cbaseline assessment (T0), assessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\nTime Frame<\/td>\nIt's a repeated measurement variable\uff0cassessment after 4 weeks of treatment (T1), assessment after 8 weeks of treatment (T2), and 3-month follow-up after completion of treatment (T3)<\/td>\n<\/tr>\n
Description<\/td>\nTic symptom severity is estimated by Yale Global Tic Severity Scale Total Tic score. The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics-scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.Lower scores indicate improvement and higher scores indicate worsening.<\/td>\nDescription<\/td>\nTic symptom severity is estimated by Yale Global Tic Severity Scale Total Tic score. The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics-scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.Lower scores indicate improvement and higher scores indicate worsening.<\/td>\nDescription<\/td>\nTic symptom severity is estimated by Yale Global Tic Severity Scale Total Tic score. The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics-scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.Lower scores indicate improvement and higher scores indicate worsening.<\/td>\nDescription<\/td>\nTic symptom severity is estimated by Yale Global Tic Severity Scale Total Tic score. The YGTSS is a clinician-rated scale used to assess tic severity over the prior week. It includes a checklist of motor and vocal tics followed by an assessment of the number, frequency, intensity, complexity, and inference of motor tics and phonic tics-scored separately. Each of these dimensions is scored on a 0 to 5 scale. The YGTSS provides three tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25) and the combined Total Tic Severity Score (0 to 50), as well as a separate Impairment dimension scored from0 to 50. The Total Tic Score (YGTSS-TTS) was used in these analyses.Lower scores indicate improvement and higher scores indicate worsening.<\/td>\nDescription<\/td>\nThe participants were asked to sort 64 cards to match either color (red, blue, yellow, or green), form (crosses, circles, triangles, or stars), or number of figures (one, two, three, four). During the task, the sorting rule changed discreetly from color to form or number of figures without the participants being informed. The participants had to shift sets accordingly and sort cards following the new sorting rule. Set shifting difficulties were indicated by preservative errors; thus, higher scores on this test represent worse performance.<\/td>\nDescription<\/td>\nThe participants were asked to sort 64 cards to match either color (red, blue, yellow, or green), form (crosses, circles, triangles, or stars), or number of figures (one, two, three, four). During the task, the sorting rule changed discreetly from color to form or number of figures without the participants being informed. The participants had to shift sets accordingly and sort cards following the new sorting rule. Set shifting difficulties were indicated by preservative errors; thus, higher scores on this test represent worse performance.<\/td>\nDescription<\/td>\nThe participants were asked to sort 64 cards to match either color (red, blue, yellow, or green), form (crosses, circles, triangles, or stars), or number of figures (one, two, three, four). During the task, the sorting rule changed discreetly from color to form or number of figures without the participants being informed. The participants had to shift sets accordingly and sort cards following the new sorting rule. Set shifting difficulties were indicated by preservative errors; thus, higher scores on this test represent worse performance.<\/td>\nDescription<\/td>\nThe participants were asked to sort 64 cards to match either color (red, blue, yellow, or green), form (crosses, circles, triangles, or stars), or number of figures (one, two, three, four). During the task, the sorting rule changed discreetly from color to form or number of figures without the participants being informed. The participants had to shift sets accordingly and sort cards following the new sorting rule. Set shifting difficulties were indicated by preservative errors; thus, higher scores on this test represent worse performance.<\/td>\nDescription<\/td>\nThe Stroop task requires participants to name the ink color of a series of color words. In the congruent condition, the color name corresponds exactly to the color of each letter; in the incongruent condition, the printed word and the actual color of each letters are different. When subjects are required to report the ink color of the word, greater difficulty is experienced when they are in the incongruent condition. This difficulty can be measured by the increase in the amount of time required to complete the task (the Stroop interference effect). The measure of executive ability is the relative response delay in the Stroop interference condition as measured by response time (RT) in the incongruent condition minus RT in the neutral condition.<\/td>\nDescription<\/td>\nThe CY-BOCS evaluates the severity of obsessions and compulsions, using ten items across five dimensions (time occupied by symptoms, interference, distress, resistance and degree of control over symptoms). The total severity score can range from 0 to 40. CY-BOCS total scores in the range of 14-24 are considered moderate, 25-30 moderate-severe and over 30 severe<\/td>\nDescription<\/td>\nIt contains 26 items and is scored on a 0-3 Likert scale. The scale consists of three subscales, which are three parts: attention deficit, hyperactivity\/impulsivity, and oppositional defiance, and can be used for the assessment of ADHD symptoms in tic symptom comorbidity in this study.<\/td>\nDescription<\/td>\nThere are 27 items quantifying symptoms such as depressed mood, hedonic capacity, vegetative functions, self-evaluation, and interpersonal behaviors. Each item consists of three statements graded in order of increasing severity from 0 to 2; children and adolescents select the one that characterized their symptoms best during the past 2 weeks. The item scores are combined into a total depression score, which ranges from 0 to 54. A higher CDI score means a higher depressive state.<\/td>\nDescription<\/td>\nThe SCARED is a 41-item self-report measure designed to screen for DSM-IV anxiety disorders. The SCARED includes 5 factors: somatic\/panic (13 items; e.g., "When I feel frightened, it is hard to breathe"), generalized anxiety (9 items; e.g., "I worry about other people liking me"), separation anxiety (8 items; e.g., "I get scared if I sleep away from home"), social phobia (7 items; e.g., "I don't like to be with people I don"t know well"), and school phobia (4 items; e.g., "I get headaches when I am at school"). The participants rated the items of each factor on a 3-point scale (0 = not true or hardly ever true, 1 = sometimes true, and 2 = true or often true). The SCARED total score, derived by adding the responses of the 41 items, ranges from 0 to 82.<\/td>\nDescription<\/td>\nIt is suitable for children aged 3 – 16 years, and a total of 48 items in this scale include six factors: conduct problems, learning problems, psychosomatic problems, impulsive-hyperactivity, anxiety, and hyperactivity index, with a total of 48 items, which are scored on a 0-3 four-level scale.<\/td>\nDescription<\/td>\nThe severity of illness subscale is designed to acquaint the patient's severity of symptoms with those of other people experiencing the same mental ailment. The CGI-S rates this severity of a 1-7 scale, with (1) representing normal symptoms, meaning the patient is not ill. The highest on the scale, (7), represents patients among the most severely ill. Right in the middle at (4), a patient will be defined as moderately ill.<\/td>\nDescription<\/td>\nThe global improvement subscale allows the practitioner to create a comparative improvement based on the baseline of the first test. These changes reflect how symptoms have or have no improves due to treatment. The 7-point CGI-I scale rates improvement with a (1) representing a 'very much improved' patient and (7) representing a patient who has become 'very much worse' due to treatment. The rating (4) represents a patient displaying no change from the treatment.<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Browse Conditions<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n194273957<\/td>\nSequence:<\/td>\n194273958<\/td>\nSequence:<\/td>\n194273959<\/td>\nSequence:<\/td>\n194273960<\/td>\nSequence:<\/td>\n194273961<\/td>\nSequence:<\/td>\n194273962<\/td>\nSequence:<\/td>\n194273963<\/td>\nSequence:<\/td>\n194273964<\/td>\nSequence:<\/td>\n194273965<\/td>\n<\/tr>\n
Mesh Term<\/td>\nTics<\/td>\nMesh Term<\/td>\nTic Disorders<\/td>\nMesh Term<\/td>\nDyskinesias<\/td>\nMesh Term<\/td>\nNeurologic Manifestations<\/td>\nMesh Term<\/td>\nNervous System Diseases<\/td>\nMesh Term<\/td>\nMovement Disorders<\/td>\nMesh Term<\/td>\nCentral Nervous System Diseases<\/td>\nMesh Term<\/td>\nNeurodevelopmental Disorders<\/td>\nMesh Term<\/td>\nMental Disorders<\/td>\n<\/tr>\n
Downcase Mesh Term<\/td>\ntics<\/td>\nDowncase Mesh Term<\/td>\ntic disorders<\/td>\nDowncase Mesh Term<\/td>\ndyskinesias<\/td>\nDowncase Mesh Term<\/td>\nneurologic manifestations<\/td>\nDowncase Mesh Term<\/td>\nnervous system diseases<\/td>\nDowncase Mesh Term<\/td>\nmovement disorders<\/td>\nDowncase Mesh Term<\/td>\ncentral nervous system diseases<\/td>\nDowncase Mesh Term<\/td>\nneurodevelopmental disorders<\/td>\nDowncase Mesh Term<\/td>\nmental disorders<\/td>\n<\/tr>\n
Mesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-list<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\nMesh Type<\/td>\nmesh-ancestor<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Sponsors<\/h3>\n\n\n\n\n\n
Sequence:<\/td>\n48512475<\/td>\nSequence:<\/td>\n48512476<\/td>\n<\/tr>\n
Agency Class<\/td>\nOTHER<\/td>\nAgency Class<\/td>\nUNKNOWN<\/td>\n<\/tr>\n
Lead Or Collaborator<\/td>\nlead<\/td>\nLead Or Collaborator<\/td>\ncollaborator<\/td>\n<\/tr>\n
Name<\/td>\nChildren's Hospital of Fudan University<\/td>\nName<\/td>\nShanghai Normal University<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Central Contacts<\/h3>\n\n\n\n\n\n\n\n\n
Sequence:<\/td>\n12061714<\/td>\n<\/tr>\n
Contact Type<\/td>\nprimary<\/td>\n<\/tr>\n
Name<\/td>\nDing Qiang, master<\/td>\n<\/tr>\n
Phone<\/td>\n18818239447<\/td>\n<\/tr>\n
Email<\/td>\njohndean@foxmail.com<\/td>\n<\/tr>\n
Phone Extension<\/td>\n201102<\/td>\n<\/tr>\n
Role<\/td>\nContact<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Design Group Interventions<\/h3>\n\n\n\n\n
Sequence:<\/td>\n68430463<\/td>\nSequence:<\/td>\n68430464<\/td>\n<\/tr>\n
Design Group Id<\/td>\n55823439<\/td>\nDesign Group Id<\/td>\n55823438<\/td>\n<\/tr>\n
Intervention Id<\/td>\n52688379<\/td>\nIntervention Id<\/td>\n52688380<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Eligibilities<\/h3>\n\n\n <\/tr>\n\n\n\n\n <\/tr>\n\n <\/tr>\n <\/tr>\n\n\n\n
Sequence:<\/td>\n30885090<\/td>\n<\/tr>\n
Gender<\/td>\nAll<\/td>\n<\/tr>\n
Minimum Age<\/td>\n8 Years<\/td>\n<\/tr>\n
Maximum Age<\/td>\n16 Years<\/td>\n<\/tr>\n
Healthy Volunteers<\/td>\nNo<\/td>\n<\/tr>\n
Criteria<\/td>\nInclusion Criteria: Meet the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders(Fifth Edition,DSM-5) for chronic tic disorder or Tourette syndrome\uff08TS\uff09; Ethnic group is Han nationality; Aged 8 ~ 16 years old; otal IQ of Wechsler Intelligence Scale for Children \u2265 80 points for subjects; Symptom severity score in Yale Global Severity Scale (YGTSS), TS patients > 13, CTD > 9; Did not receive any drug (including traditional Chinese medicine) treatment 4 weeks before enrollment; Obtain written informed consent from children and guardians Exclusion Criteria: Epilepsy, cardiovascular disease Patients with schizophrenia, mental retardation, autism spectrum disorder, bipolar disorder and major depression who meet the DSM-5 diagnostic criteria; Receiving systematic traditional Chinese medicine treatment one month before enrollment or currently; Receiving systematic psychotherapy one month before enrollment or currently; Receive systematic physical therapy one month before enrollment or currently Those who cannot follow the doctor's advice or refuse to cooperate; Those with obvious abnormal laboratory test results (AST or ALT \u2265 2 times of the upper limit of normal value; bun \u2265 1.5 times of the upper limit of normal value; Cr \u2265 1.2 times of the upper limit of normal value); Prolongation of QTc interval (QTc \u2265 450 ms in men or \u2265 470 MS in women);<\/td>\n<\/tr>\n
Adult<\/td>\nFalse<\/td>\n<\/tr>\n
Child<\/td>\nTrue<\/td>\n<\/tr>\n
Older Adult<\/td>\nFalse<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Calculated Values<\/h3>\n\n\n\n <\/tr>\n <\/tr>\n\n <\/tr>\n <\/tr>\n\n <\/tr>\n\n\n\n\n\n\n\n\n <\/tr>\n<\/table><\/div>\n
\n

Designs<\/h3>\n

Sequence:<\/td>\n254114749<\/td>\n<\/tr>\n
Number Of Facilities<\/td>\n1<\/td>\n<\/tr>\n
Registered In Calendar Year<\/td>\n2022<\/td>\n<\/tr>\n
Were Results Reported<\/td>\nFalse<\/td>\n<\/tr>\n
Has Us Facility<\/td>\nFalse<\/td>\n<\/tr>\n
Has Single Facility<\/td>\nTrue<\/td>\n<\/tr>\n
Minimum Age Num<\/td>\n8<\/td>\n<\/tr>\n
Maximum Age Num<\/td>\n16<\/td>\n<\/tr>\n
Minimum Age Unit<\/td>\nYears<\/td>\n<\/tr>\n
Maximum Age Unit<\/td>\nYears<\/td>\n<\/tr>\n
Number Of Primary Outcomes To Measure<\/td>\n8<\/td>\n<\/tr>\n
Number Of Secondary Outcomes To Measure<\/td>\n8<\/td>\n<\/tr>\n
\n\n\n\n\n\n\n\n <\/tr>\n <\/tr>\n <\/tr>\n <\/tr>\n\n\n
Sequence:<\/td>\n30630855<\/td>\n<\/tr>\n
Allocation<\/td>\nRandomized<\/td>\n<\/tr>\n
Intervention Model<\/td>\nParallel Assignment<\/td>\n<\/tr>\n
Observational Model<\/td>\n<\/td>\n<\/tr>\n
Primary Purpose<\/td>\nTreatment<\/td>\n<\/tr>\n
Time Perspective<\/td>\n<\/td>\n<\/tr>\n
Masking<\/td>\nDouble<\/td>\n<\/tr>\n
Investigator Masked<\/td>\nTrue<\/td>\n<\/tr>\n
Outcomes Assessor Masked<\/td>\nTrue<\/td>\n<\/tr>\n<\/table><\/div>\n
\n

Responsible Parties<\/h3>\n\n\n\n\n\n <\/tr>\n\n <\/tr>\n<\/table><\/div>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"

Studies Study First Submitted Date 2022-03-18 Study First Posted Date 2022-05-05 Last Update Posted Date 2022-10-24 Start Month Year June 1, 2024 Primary Completion Month Year December 31, 2026 Verification Month Year October 2022 Verification Date 2022-10-31 Last Update Posted Date 2022-10-24 Detailed Descriptions Sequence: 20802855 Description This study intends to investigate the efficacy of […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":173882,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/173881"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=173881"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/173881\/revisions"}],"predecessor-version":[{"id":602696,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/173881\/revisions\/602696"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/173882"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=173881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=173881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=173881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Sequence:<\/td>\n28997435<\/td>\n<\/tr>\n
Responsible Party Type<\/td>\nPrincipal Investigator<\/td>\n<\/tr>\n
Name<\/td>\nDing Qiang<\/td>\n<\/tr>\n
Title<\/td>\nClinical Psychotherapist<\/td>\n<\/tr>\n
Affiliation<\/td>\nChildren's Hospital of Fudan University<\/td>\n<\/tr>\n